Drug intelligence / Profile preview

L304

Development stage: Preclinical
Lead developer: Neutrolis
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical, Ophthalmic

Overview

L304 is a novel DNase enzyme developed by Neutrolis for the treatment of eye diseases, specifically targeting Neutrophil Extracellular Traps (NETs) as a potential therapy for dry eye disease. It is generated using Neutrolis's proprietary exDNASE platform. The drug acts by degrading NETs, which are implicated in autoimmune and inflammatory conditions affecting the eye. The development of L304 builds on pioneering research into topical DNase use in ocular conditions, with early clinical trials supporting its feasibility in moderate to severe dry eye disease and ocular graft-versus-host disease[1].

Targets

eDNA (Extracellular DNA)

Beyond the preview

Go deeper on L304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L304.

Explore the full profile